Abstract
This chapter describes the design, main findings, relevance, and limitations of the landmark Prostate Cancer Prevention Trial (PCPT), which randomized men to finasteride versus placebo and followed them for 7 years. It found a major reduction in prostate cancer incidence but also a higher proportion of high-risk cancer in men diagnosed with prostate cancer. The study did not address the more important oncological outcomes of disease-specific and overall survival. Secondary analyses of PCPT outcomes favored the finasteride arm and suggested that the risk of high-risk cancer is not increased. Linkage analysis of participants from PCPT to Medicare claims data suggested no adverse long-term cardiac, endocrine, or sexual effects.
Keywords
FinasterideProstate cancerMedicineOncologyInternal medicineGynecologyCancerDiseaseProstate
Related Publications
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline
Abstract Objective To update the “Testosterone Therapy in Men With Androgen Deficiency Syndromes” guideline published in 2010. Participants The participants include an Endocrine...
Epidemiology of Prostate Cancer
Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. Prostate cancer may be asymptomatic at the early stage a...
A randomized trial of choice of treatment in prostate cancer: the effect of intervention on the treatment chosen
OBJECTIVE To determine whether different approaches in the choice of treatment affect the treatment chosen by the patient for prostate cancer. PATIENTS AND METHODS We conducted ...
Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden
Active surveillance has become the dominant management for low-risk prostate cancer among men in Sweden, with the highest rates yet reported and almost complete uptake for very-...
Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US
Importance Active surveillance (AS) is endorsed by clinical guidelines as the preferred management strategy for low-risk prostate cancer, but its use in contemporary clinical pr...
Publication Info
- Year
- 2021
- Type
- book-chapter
- Pages
- 7-12
- Citations
- 2085
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
2085
OpenAlex
3
Influential
0
CrossRef
Cite This
Niranjan Sathianathen
(2021).
The Influence of Finasteride on the Development of Prostate Cancer.
Oxford University Press eBooks
, 7-12.
https://doi.org/10.1093/med/9780190655341.003.0002
Identifiers
- DOI
- 10.1093/med/9780190655341.003.0002